drugset / Trial / NCT05542264
A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A Clinical Study that will look at an investigational medication, SEP-363856 (called "study medication") in patients with schizophrenia, and assess wether it affectsbody-weight associated parameters. This study is accepting male and female participants age 18 years to 65 years. This study will be conducted in approximately 6 study sites in the United States. Participation could last up to 13 weeks.
Timeline
- Start
- 2022-11-15
- Primary completion
- 2024-02-12
- Completion
- 2024-02-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aripiprazole | Other / unclassified | — | Oral |
| Comparator | Olanzapine | Small molecule | — | Oral |
| Comparator | Quetiapine | Small molecule | — | Oral |
| Comparator | Risperidone | Other / unclassified | — | Oral |
| Subject | Ulotaront | Small molecule | — | — |